Clinical trials: Ivermectin
Lice; Head Lice
A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5%
A Multi-Center, Double-Blind, Randomized, Placebo controlled, Parallel-group study, comparing Ivermectin Lotion, 0.5%
- Trial name
- NCT03257943
- Testing
- Ivermectin Lotion, 0.5%, SKLICE (ivermectin) Lotion, 0.5%, Vehicle of the Test product
- Where
- United States
- Volunteers
- 413 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
COVID-19
A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention
A multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy and safety of oral ivermectin tablets versus placebo for COVID-19 prophylaxis
- Trial name
- SAIVE (NCT05305560)
- Testing
- Ivermectin Tablets
- Where
- Bulgaria
- Volunteers
- 400 people
- Sponsor
- MedinCell S.A
Papulopustular Rosacea
CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study
Study objectives: To compare efficacy and safety of Ivermectin 1% cream versus metronidazole 0.75% cream in subjects with papulopustular rosacea after 16-week topical treatment.
- Trial name
- ATTRACT (NCT01493947)
- Testing
- Ivermectin 1% cream, Metronidazole 0.75% cream
- Where
- 60 sites in Bulgaria, Czechia and 8 more
- Volunteers
- 962 people
- Sponsor
- Galderma R&D
Lice Infestations
Ivermectin in the Treatment of Head Lice
The purpose of this study is to compare 2 single doses of ivermectin as tablets with 2 single applications of malathion 0.5% lotion (Days 1 and 8) in clearing head lice, in patients who have recently used standard head lice…
- Trial name
- NCT00819520
- Testing
- ivermectin, malathion
- Where
- 4 sites in France, Ireland and 2 more
- Volunteers
- 812 people
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Healthy
Ivermectin Solution Bioequivalence Study - Fasted
The purpose of this study was to compare the pharmacokinetic and bioavailability profile (rate and amount of absorption into the bloodstream) of a test formulation of ivermectin solution 1 mg/ml with a marketed reference…
- Trial name
- NCT00921154
- Testing
- ivermectin
- Where
- Ireland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Pediculosis Capitis
Efficacy and Safety of Topical 0.5% Ivermectin Lotion for the Treatment of Head Lice Infestation in Filipinos
This is a randomized, double-blind, placebo-controlled clinical study evaluating the efficacy and safety of a single application of 0.5% ivermectin lotion in Filipino subjects with head lice.
- Trial name
- NCT03286101
- Testing
- 0.5% Ivermectin lotion, Vehicle
- Where
- Philippines
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- United Laboratories
Pediculus Humanus Capitis (Head Lice)
Dose Ranging Study of Ivermectin Treatment Conditioner in Subjects With Head Lice Infestation
This is a Phase 2 single center study designed to compare the safety, local tolerability, and efficacy of 3 strengths of ivermectin treatment conditioner to placebo.
- Trial name
- NCT00857948
- Testing
- ivermectin treatment conditioner
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Topaz Pharmaceuticals Inc
Healthy Volunteers
Bioavailability Pilot Study of Versus W0035 Versus Stromectol
Ivermectin is prescribed for the treatment of helminthic infections sensitive to ivermectin. However, it is currently only available as a tablet formulation.
- Trial name
- NCT03717558
- Testing
- ivermectin T1, ivermectin T2, ivermectin T3
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pierre Fabre Dermatology
COVID-19 Drug Treatment
Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19
In the context of COVID-19 pandemic, a report on ivermectin suppression of SARS-CoV-2 viral replication in cell cultures has been published, and the use of this medication seems to be potentially useful for the therapy.
- Trial name
- NCT04381884
- Testing
- IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.
- Where
- 3 sites in Argentina
- Volunteers
- 45 people
- Sponsor
- Laboratorio Elea Phoenix S.A.